Klin Farmakol Farm. 2019;33(3):5-10

Generic drugs: theory and praxis

Karel Urbánek
Ústav farmakologie LF UP a FN Olomouc

Generic drugs are copies of original medicinal products that do not have to undergo a demanding preclinical and clinical research process for their approval. They must be chemically identical to the original product and have the identic drug formulation. The main benefit of generic medicines is their significantly lower cost, which results from cost savings on preclinical and especially clinical research and development. Without generic medicines, current health systems could not work or be funded. The very concept of generic medicines has never been challenged and the principles of their registration have in principle fully proved its worth. Changing treatment with one medicinal product for another may pose some risks, but such situations are quite exceptional. Doctors and pharmacists should be well informed about them and should not underestimate the patient‘s education in this regard.

Keywords: generic medicinal products, original medicinal products, biosimilars, generic substitution

Published: October 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek K. Generic drugs: theory and praxis. Klin Farmakol Farm. 2019;33(3):5-10.
Download citation

References

  1. Morais JA, Lobato Mdo R. The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol. 2010 Mar; 106(3): 221-225. Go to original source... Go to PubMed...
  2. Sullivan JO, Blake K, Berntgen M, Salmonson T, Welink J; Pharmacokinetics Working Party. Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines. Clin Pharmacol Ther. 2018 Sep; 104(3): 539-545. Go to original source... Go to PubMed...
  3. Hronová K. Generika a jejich postavení v léčbě, rizika záměny v lékárnách. Interní Med. 2016; 18(4): 191-193. Go to original source...
  4. SÚKL. Reakce na články o generické substituci. Dostupné z: http://www.sukl.cz
  5. Bhaumik S. Medical regulator urges doctors to prescribe generic drugs. BMJ 2013; 346: f564. Go to original source... Go to PubMed...
  6. Rada EU. Opatření EU na podporu výrobců generických léčiv. Dostupné na: https://www.consilium.europa.eu/cs/press/press-releases/2019/02/20/eu-measures-in-support-of-generic-pharmaceuticals-producers/
  7. Bez generik nejsou zdravotní systémy udržitelné. Za deset let ušetřily už 136 miliard korun. Dostupné na: https://www.zdravotnickydenik.cz/2018/09/bez-generik-nejsou-zdravotni-systemy-udrzitelne-za-deset-let-usetrily-uz-136-miliard-korun/
  8. Wouters OJ, Kanavos PG, McKee M. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending. Milbank Q. 2017 Sep; 95(3): 554-601. Go to original source... Go to PubMed...
  9. Gauzit R, Lakdhari M. Generic antibiotic drugs: is effectiveness guaranteed? Med Mal Infect. 2012 Apr; 42(4): 141-148. Go to original source... Go to PubMed...
  10. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect, DiS. 2008 May; 61(1): 76-79. Go to original source... Go to PubMed...
  11. Moet GJ, Watters AA, Sader HS, Jones RN. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagn Microbiol Infect, DiS. 2009 Nov; 65(3): 319-322. Go to original source... Go to PubMed...
  12. Tattevin P, Crémieux AC, Rabaud C, Gauzit R. Efficacy and quality of antibacterial generic products approved for human use: a systematic review. Clin Infect, DiS. 2014 Feb; 58(4): 458-469. Go to original source... Go to PubMed...
  13. Urbánek K, Šiller M, Večeřa R, Zachařová A, Matušková Z. Porovnání originálních a generických přípravků karbapenemových antibiotik. Klin Farmakol Farm 2011; 25(1): 11-17.
  14. Vetchý D, Rabišková M, Švarcová M, Sýkora T, Häring A. Porovnání vybraných perorálních originálních a generických léků používaných v kardiologii na základě disoluční studie. Klin Farmakol Farm 2005; 19: 84-88.
  15. Strojil J. Biosimilars - specifika schvalovacího procesu v EU. Klin Farmakol Farm 2014: 28(1): 14-18.
  16. Ošlejšková H. Možnosti využití generických antiepileptik v terapii epilepsií v každodenní praxi. Neurol. pro Praxi, 2005; 4: 227-230.
  17. Kesselheim AS, Bykov K, Gagne JJ, Wang SV, Choudhry NK. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Neurology. 2016 Oct 25; 87(17): 1796-1801. Go to original source... Go to PubMed...
  18. Polard E, Nowak E, Happe A, Biraben A, Oger E; GENEPI Study Group. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Pharmacoepidemiol Drug Saf. 2015 Nov; 24(11): 1161-1169. Go to original source... Go to PubMed...
  19. Lang JD, Kostev K, Onugoren MD, et al. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany. Ann Neurol. 2018 Dec; 84(6): 918-925. Go to original source... Go to PubMed...
  20. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy. 1993 Jul-Aug; 13(4): 359-368. Go to PubMed...
  21. Saseen JJ, Porter JA, Barnette DJ, Bauman JL, Zajac EJ Jr, Carter BL. Postabsorption concentration peaks with brand-name and generic verapamil: a double-blind, crossover study in elderly hypertensive patients. J Clin Pharmacol. 1997 Jun; 37(6): 526-534. Go to original source... Go to PubMed...
  22. Manzoli L, Flacco ME, Boccia S. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016 Apr; 31(4): 351-368. Go to original source... Go to PubMed...
  23. Hennessey JV, Malabanan AO, Haugen BR, Levy EG. Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr Pract. 2010 May-Jun; 16(3): 357-370. Go to original source... Go to PubMed...
  24. Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord. 2010 Apr 14; 11: 68. Go to original source... Go to PubMed...
  25. Ringe JD, Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. 2009 Dec; 30(2): 213-221. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.